Main Article Content
Perhexiline maleate in the management of patients with angina pectoris
Abstract
In a single-blind study lasting 6 months an entirely new anti-anginal preparation, perhexiline maleate (Pexid), was prescribed in a dose of 200 mg b.d. to 21 patients suffering from angina pectoris. There was a statistically significant reduction in the average number of anginal attacks over the 6-month period in each subgroup studied. Half the cases studied were asymptomatic at the end of the period. Side-effects were reported in 16 patients; dizziness, headache, weakness, loss of weight and decreased libido being the commonest symptoms. No patient withdrew from the trial because of these symptoms, which disappeared within 4 weeks of continued therapy.
S. Afr. Med. J., 48, 904 (1974).
S. Afr. Med. J., 48, 904 (1974).